• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Concurrent chemoradiotherapy for stage III non-small cell lung cancer: correct clinical management as the basis to move beyond.III期非小细胞肺癌的同步放化疗：正确的临床管理是取得进展的基础。
Ann Transl Med. 2018 Nov;6(Suppl 1):S65. doi: 10.21037/atm.2018.10.38.
2
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).诱导化疗和同期放化疗后可切除 IIIA(N2)和部分 IIIB 期非小细胞肺癌患者的手术与根治性同期放化疗增敏的 III 期研究（ESPATUE）
J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2.
3
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.标准剂量与高剂量适形放疗联合并巩固使用卡铂加紫杉醇，联合或不联合西妥昔单抗治疗IIIA期或IIIB期非小细胞肺癌患者（RTOG 0617）：一项随机、二乘二析因3期研究。
Lancet Oncol. 2015 Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0. Epub 2015 Jan 16.
4
How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?如何优化不能手术的 III 期非小细胞肺癌的同期放化疗？
Lung Cancer. 2014 Feb;83(2):117-25. doi: 10.1016/j.lungcan.2013.11.017. Epub 2013 Dec 1.
5
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.老年与年轻Ⅲ期非小细胞肺癌患者同步放化疗个体患者数据的汇总分析：基于美国国立癌症研究所合作组研究
J Clin Oncol. 2017 Sep 1;35(25):2885-2892. doi: 10.1200/JCO.2016.71.4758. Epub 2017 May 11.
6
Phase II study of vinorelbine plus carboplatin with concurrent radiotherapy in elderly patients with non-small cell lung cancer.长春瑞滨联合卡铂同期放疗治疗老年非小细胞肺癌的 II 期研究。
Jpn J Clin Oncol. 2020 Mar 9;50(3):318-324. doi: 10.1093/jjco/hyz179.
7
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.特泽莫替尼（L-BLP25）联合放化疗对比安慰剂治疗 III 期非小细胞肺癌（START）：一项随机、双盲、III 期临床试验。
Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.
8
Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.接受根治性同步放化疗的Ⅲ期非小细胞肺癌患者中，淋巴结标准化摄取值对生存的预后意义
Am J Clin Oncol. 2016 Aug;39(4):355-62. doi: 10.1097/COC.0000000000000070.
9
Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium.荷兰和比利时III期非小细胞肺癌患者序贯与同步放化疗的治疗差异
Clin Oncol (R Coll Radiol). 2017 Nov;29(11):e177-e185. doi: 10.1016/j.clon.2017.07.012. Epub 2017 Aug 2.
10
[Analysis of concurrent chemoradiotherapy in patients with stage III non-small cell lung cancer after two cycles of induction chemotherapy].[诱导化疗两个周期后Ⅲ期非小细胞肺癌患者同步放化疗分析]
Zhongguo Fei Ai Za Zhi. 2005 Feb 20;8(1):48-50. doi: 10.3779/j.issn.1009-3419.2005.01.11.

引用本文的文献

1
Budget impact analysis of durvalumab consolidation therapy vs no consolidation therapy after chemoradiotherapy in stage III non-small cell lung cancer in the context of the Chilean health care system.在智利医疗体系下，比较 durvalumab 巩固治疗与放化疗后不进行巩固治疗用于 III 期非小细胞肺癌的预算影响分析。
PLoS One. 2024 Jul 26;19(7):e0307473. doi: 10.1371/journal.pone.0307473. eCollection 2024.

本文引用的文献

1
Increased incidence, morbidity and mortality rates for lung cancer in women in Brazil between 2000 and 2014: An analysis of three types of sources of secondary data.2000 年至 2014 年期间巴西女性肺癌发病率、发病率和死亡率上升：对三种类型二级数据来源的分析。
Lung Cancer. 2018 Nov;125:77-85. doi: 10.1016/j.lungcan.2018.09.005. Epub 2018 Sep 12.
2
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
3
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors.放疗联合免疫检查点抑制剂的远隔效应。
J Hematol Oncol. 2018 Aug 16;11(1):104. doi: 10.1186/s13045-018-0647-8.
4
Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?局部晚期非小细胞肺癌：免疫疗法会是新的契机吗？
J Thorac Dis. 2018 May;10(Suppl 13):S1461-S1467. doi: 10.21037/jtd.2017.12.53.
5
Variations in Initiation Dates of Chemotherapy and Radiation Therapy for Definitive Management of Inoperable Non-Small Cell Lung Cancer Are Associated With Decreases in Overall Survival.根治性放化疗起始时间的变化与不可手术非小细胞肺癌患者总生存时间的降低有关。
Clin Lung Cancer. 2018 Jul;19(4):e381-e390. doi: 10.1016/j.cllc.2018.03.007. Epub 2018 Mar 17.
6
Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.将精确放疗与分子靶向和免疫调节剂相结合：美国放射肿瘤学会指南。
Lancet Oncol. 2018 May;19(5):e240-e251. doi: 10.1016/S1470-2045(18)30096-2.
7
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
8
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.Durvalumab 用于 III 期非小细胞肺癌放化疗后的治疗。
N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
9
Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer.局部晚期非小细胞肺癌同步放化疗的急性和晚期毒性反应
Cancers (Basel). 2017 Sep 8;9(9):120. doi: 10.3390/cancers9090120.
10
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.早期和局部晚期非小细胞肺癌（NSCLC）：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222.

Concurrent chemoradiotherapy for stage III non-small cell lung cancer: correct clinical management as the basis to move beyond.

作者信息

Costa Guilherme Jorge, Ferreira Carlos Gil, Thuler Luiz Claudio Santos

机构信息

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) and Hospital de Câncer de Pernambuco, Recife, Pernambuco, Brazil.

Oncoclinicas Institute for Research and Education, São Paulo, Brazil.

出版信息

Ann Transl Med. 2018 Nov;6(Suppl 1):S65. doi: 10.21037/atm.2018.10.38.

DOI:10.21037/atm.2018.10.38
PMID:30613640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6291529/
Abstract
摘要